Figure 9

Kaplan–Meier curve and log-rank test for tumor budding pathway SNP predictive of OS in KRAS wild-type mCRC patients. Patients with MMP2 rs243865 Any T carriers have longer OS (28.5 vs. 20.3 mo; p = 0.021) compared to C/C carriers.
Kaplan–Meier curve and log-rank test for tumor budding pathway SNP predictive of OS in KRAS wild-type mCRC patients. Patients with MMP2 rs243865 Any T carriers have longer OS (28.5 vs. 20.3 mo; p = 0.021) compared to C/C carriers.